Document:

Exhibit 10.31

 

FIFTH AMENDMENT TO SECOND AMENDED AND
RESTATED 

CREDIT AGREEMENT

 

This FIFTH AMENDMENT
TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of February 26, 2016 (the “Effective
Date”), is entered into by and among PACIFIC ETHANOL HOLDING CO. LLC, a Delaware limited liability company (“Pacific
Holding”), PACIFIC ETHANOL MADERA LLC, a Delaware limited liability company (“Madera”), PACIFIC ETHANOL
COLUMBIA, LLC, a Delaware limited liability company (“Boardman”), PACIFIC ETHANOL STOCKTON LLC, a Delaware
limited liability company (“Stockton”), and PACIFIC ETHANOL MAGIC VALLEY, LLC, a Delaware limited liability
company (“Burley” and, together with Pacific Holding, Madera, Boardman and Stockton, the “Borrowers”),
Pacific Holding, as Borrowers’ Agent, PE OP CO., a Delaware corporation (f/k/a New PE Holdco LLC), as Pledgor (the “Pledgor”
and together with Borrowers and Pacific Holding as Borrower’s Agent, the “Borrower Parties”), each of
the Lenders, WELLS FARGO BANK, N.A., as administrative agent for the Lenders (“Administrative Agent”), and
WELLS FARGO BANK, N.A., as collateral agent for the Senior Secured Parties (“Collateral Agent”). Capitalized
terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Credit Agreement (as hereinafter
defined).

 

RECITALS

 

WHEREAS, the
Borrower Parties, the Lenders party thereto, Administrative Agent, Collateral Agent, and Accounts Bank, entered into that certain
Second Amended and Restated Credit Agreement dated as of October 29, 2012 (as amended to date, the “Credit Agreement”);

 

WHEREAS, pursuant
to the Credit Agreement, three separate commitments were extended to the Borrowers, a Tranche A-1 Term Loan, a Tranche A-2 Term
Loan and a Revolving Loan, all as further described in the Credit Agreement, including Sections 2.01 through 2.03 thereof;

 

WHEREAS, the Revolving
Loan Commitment has been terminated and each of the Revolving Lenders have ceased being Lenders under the Credit Agreement;

 

WHEREAS, Credit
Suisse Loan Funding LLC (“Credit Suisse”) and Pacific Ethanol, Inc. constitute 100% of the Tranche A-1 Lenders;

 

WHEREAS, Pacific
Ethanol, Inc. constitutes the sole Tranche A-2 Lender;

 

WHEREAS, the Borrowers
desire to prepay 100% of the Tranche A-1 Term Loans and other Obligations held by Credit Suisse (the “Loan Prepayment”),
and Credit Suisse has agreed to waive any Make-Whole Amount due and payable in connection with the Loan Prepayment; and

 

WHEREAS, following
the Loan Prepayment, Pacific Ethanol, Inc. shall constitute the sole Lender under the Credit Agreement and desires to amend and
modify the Credit Agreement as set forth herein;

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged and confirmed, the parties hereto
hereby agree as follows:

 

	SECTION 1.	Consent
and Waiver Regarding Prepayment. As of the date hereof, the following amounts are due (collectively, the “Prepayment
Amount”): (A) the principal amount of Tranche A-1 Term Loans held by Credit Suisse in an amount equal to$17,003,037.06;
(B) the accrued interest in respect thereof through February 23, 2016 in an amount equal to $156,790.30, with interest accruing
after February 23, 2016 at the per diem rate of $6,271.61 until payment in full is received; and (C) the accrued but unpaid fees
and costs of Administrative Agent and Collateral Agent, including its attorneys fees and costs, in an amount equal to $52,757.16
(the “Agent Fees”). Notwithstanding any provision of the Credit Agreement, (i) each of the Lenders hereby consents
to the Borrowers’ effecting the Loan Prepayment by (x) paying to Credit Suisse on the date hereof an amount equal to the
Prepayment Amount (less the Agent Fees) without any requirement that such prepayment be made in accordance with any waterfall provision
in the Credit Agreement or any portion thereof otherwise be distributed to any other Lender, and (y) paying to the Administrative
Agent on the date hereof an amount equal to the Agent Fees, and (ii) Credit Suisse hereby waives any and all prepayment premiums
or other amounts (other than the Prepayment Amount) due and payable to Credit Suisse (including, without limitation, the Make-Whole
Amount provided by Section 3.15 of the Credit Agreement) in connection with the Loan Prepayment. Each of the Administrative Agent
and the Lenders waives any notice requirement in connection with such Loan Prepayment. In addition to the Prepayment Amount, Borrowers
will be obligated to, and shall promptly, pay Administrative Agent’s and Collateral Agent’s fees and reasonable, out-of-pocket
fees and costs related to this Amendment and the consummation thereof (including the fees and costs of the Administrative Agent’s
and Collateral Agent’s counsel).
	 	 	 

 

 

    	 	1	 

     

    

 

	SECTION 2.	Amendments.
The Credit Agreement is hereby amended as follows:
	 	 
	 	2.1	Section
10.06(b) of the Credit Agreement is hereby amended and restated to read as follows:
	 	 	 
	 	“(b)Upon
any notice of resignation by any Agent or upon the removal of any Agent by the proper Persons pursuant to Section 10.06(a), the
Required Lenders of the Revolving Loan Class and the Required Lenders of the Tranche A-1 Term Loan Class shall appoint a successor
Collateral Agent or Administrative Agent, as applicable, hereunder and under each other Financing Document, or the Required Lenders
of the Revolving Loan Class, the Required Lenders of the Tranche A-1 Term Loan Class and the Required Senior Lenders shall appoint
a successor Accounts Bank.”
	 	 	 
	 	2.2	Section
10.06(c) of the Credit Agreement is hereby amended and restated to read as follows:
	 	 	 
	 	“(c)If no successor
Agent has been appointed by the proper Persons under Section 10.06(b) within thirty (30) days after the date such notice of resignation
was given by such Agent or the proper Persons elected to remove such Agent under Section 10.06(a), and provided that no Default
or Event of Default has occurred and is continuing, the Borrowers may appoint a replacement Agent within the immediately succeeding
fifteen (15) days.”

  

	SECTION 3.	Payment
of Costs and Fees. Each Borrower (i) reaffirms its obligations under Section 11.07 of the Credit Agreement and (ii) without
limiting the provisions set forth in Section 11.07 of the Credit Agreement, acknowledges, consents and agrees that it shall promptly
pay, upon receipt of invoices therefor, to the Administrative Agent, the Collateral Agent and each Lender all reasonable out-of-pocket
costs, fees, expenses and charges of every kind in connection with the preparation, negotiation, execution and delivery of this
Amendment incurred by or on behalf of such Persons, including, without limitation, the reasonable fees and disbursements of Kelley
Drye & Warren LLP, counsel to the Administrative Agent and the Collateral Agent.
	 	 	 

 

    	 	2	 

     

    

 

	SECTION 4.	Acknowledgements.
	 	 
	 	4.1.	Reaffirmation of Obligations.
Each Borrower Party hereby (a) reaffirms, acknowledges, confirms and agrees to its respective guarantees, pledges and grants of
security interests and other commitments and Obligations under the Financing Documents and (b) confirms and agrees that the Financing
Documents and all guarantees, pledges and grants of security interests and other commitments and Obligations thereunder shall continue
to be in full force and effect following the effectiveness of this Amendment. All Obligations under the Credit Agreement and the
other Financing Documents owing by the Borrower Parties to the Administrative Agent, the Collateral Agent, the Accounts Bank and
each Lender, as the case may be, are unconditionally owing by the Borrower Parties to the Administrative Agent, the Collateral
Agent, the Accounts Bank and each Lender, as the case may be, without offset, defense or counterclaim of any kind, nature or description
whatsoever.
	 	 	 
	 	4.2.	Acknowledgement of Security Interests. Each Borrower Party hereby acknowledges, confirms and agrees that the Collateral
    Agent, for itself and the benefit of Senior Secured Parties, has and shall continue to have valid, enforceable and perfected
    first-priority liens (subject only to Permitted Liens) upon and security interests in the Collateral granted to the Collateral
    Agent, for itself and the benefit of Senior Secured Parties, pursuant to the Financing Documents.
	 	 	 
	 	4.3.	Binding Effect of Documents.
Each Borrower Party hereby acknowledges, confirms and agrees that: (i) each of the Financing Documents to which it is a party has
been duly executed and delivered to the Administrative Agent, the Collateral Agent, the Accounts Bank and the Lenders party thereto
by it, and each is in full force and effect as of the Effective Date, (ii) the agreements and obligations of such Borrower Party
contained in the Credit Agreement, in each of the other Financing Documents and in this Amendment constitute the legal, valid and
binding obligations of such Borrower Party, enforceable against such Borrower Party in accordance with their respective terms,
and such Borrower Party has no valid defense to the enforcement of the obligations under the Credit Agreement or the other Financing
Documents, except as enforceability may be limited by bankruptcy, insolvency, moratorium, reorganization or other similar laws
limiting creditors rights generally and except as enforceability may be limited by general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law) and (iii) the Administrative Agent, the Collateral
Agent, the Accounts Bank and each Lender are and shall be entitled to the rights, remedies and benefits provided for in the Financing
Documents and under applicable law or at equity.

 

	SECTION 5.	Representations
and Warranties of Borrower Parties. Each of the Borrower Parties hereby represents and warrants in favor of the Administrative
Agent, the Collateral Agent, the Accounts Bank and each Lender as follows:
	 	 	 
	 	5.1.	The execution, delivery
and performance by such Borrower Party of this Amendment are within such Borrower Party’s powers and have been duly authorized
by all necessary action on the part of such Borrower Party.
	 	 	 

 

    	 	3	 

     

    

 

	 	5.2	This Amendment has been
duly executed and delivered by such Borrower Party and this Amendment constitutes a legal, valid and binding obligation of such
Borrower Party enforceable in accordance with its terms except as enforceability may be limited by bankruptcy, insolvency, moratorium,
reorganization or other similar laws limiting creditors rights generally and except as enforceability may be limited by general
principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).
	 	 	 
	 	5.3.	The execution, delivery
or performance of this Amendment by such Borrower Party (i) does not require any consent or approval of, registration of filing
with, or any other action by, any Person (including, without limitation, any Governmental Authority) except such as have been obtained
or made and are in full force and effect, (ii) will not violate the organizational or governing documents of any Borrower Party
and (iii) will not violate any applicable Law or any Contractual Obligation applicable to or binding upon such Borrower Party or
any of their respective properties or assets.
	 	 	 
	 	5.4.	No event has occurred or
is continuing, that would constitute a Default or an Event of Default under the Credit Agreement or any other Financing Document.
	 	 	 
	 	5.5.	As of the Effective Date
no litigation by, investigation known to such Borrower Party by, or proceeding of, any Governmental Authority is pending or, to
the knowledge of such Borrower Party, has been threatened against such Borrower Party which (i) challenges such Borrower Party’s
right, power, or competence to enter into this Amendment or perform any of its obligations under this Amendment or the validity
or enforceability of this Amendment or any action taken under this Amendment or (ii) is reasonably likely, if adversely decided,
to have a Material Adverse Effect.
	 	 	 
	 	5.6.	After giving effect to
this Amendment, the representations and warranties of such Borrower Party contained in the Credit Agreement and the other Financing
Documents are true and correct in all material respects (provided, that if any representation or warranty is by its terms qualified
by concepts of materiality, such representation shall be true and correct in all respects) on and as of the Effective Date with
the same effect as if such representations and warranties had been made on and as of such date, except that any such representation
or warranty which is expressly made only as of a specified date need be true only as of such date.

 

	SECTION 6.	Conditions
to Effectiveness of this Amendment. This Amendment shall be effective only (i) if and when signed by, and when counterparts
hereof shall have been delivered to the Administrative Agent (by hand delivery, mail, telecopy or other electronic transmission)
by, the Borrower Parties and the Lenders, and (ii) when the Borrower Parties shall have paid (A) an amount equal to the Prepayment
Amount (less the Agent Fees) to Credit Suisse, and (B) an amount equal to the Agent Fees to the Administrative Agent.
	 	 	 

 

    	 	4	 

     

    

	SECTION 7.	Effect
on the Financing Documents.
	 	 	 
	 	7.1.	Except
as set forth in this Amendment, the Credit Agreement and each of the other Financing Documents shall be and remain unchanged and
in full force and effect in accordance with their respective terms, are hereby ratified and confirmed in all respects and the Administrative
Agent, the Collateral Agent, the Accounts Bank and each Lender expressly reserves the right to require strict compliance with the
terms of the Credit Agreement (and, following the Effective Date, the Credit Agreement, as amended by this Amendment) and the other
Financing Documents. The execution, delivery, and performance of this Amendment shall not operate as a modification or waiver of
any right, power, or remedy of any Agent or any Lender under the Credit Agreement (and, following the Effective Date, , the Credit
Agreement, as amended by this Amendment) or any other Financing Document and no such action shall be construed as (i) a waiver
or forbearance of any of the Administrative Agent’s, the Collateral Agent’s, the Accounts Bank’s or the Lenders’
rights, remedies, and powers against the Borrowers, any other Borrower Party or the Collateral or (ii) a waiver of any Default
or Event of Default. Notwithstanding any provision of this Amendment, nothing herein shall adversely affect the rights, remedies,
duties, liabilities, obligations and/or responsibilities of any Lender that has not consented to the terms hereof to the extent
such consent may be required pursuant to the Credit Agreement, including Section 11.01 thereof.
	 	 	 
	 	7.2.	Upon
and after the effectiveness of this Amendment, each reference in the Credit Agreement to “this Agreement,” “hereunder,”
“herein,” “hereof” or words of like import referring to the Credit Agreement, and each reference in the
other Financing Documents to “the Credit Agreement,” “thereunder,” “therein,” “thereof”
or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as modified by
this Amendment.
	 	 	 
	 	7.3.	To
the extent that any terms and conditions in any of the Financing Documents shall contradict or be in conflict with any terms or
conditions of the Credit Agreement, after giving effect to this Amendment, such terms and conditions are hereby deemed modified
or amended accordingly to reflect the terms and conditions of the Credit Agreement as modified hereby (except to the extent that
such contradiction or conflict is expressly permitted by this Amendment).
	 	 	 
	SECTION 8.	Ratification.
Except as expressly modified hereby or waived herein, the Credit Agreement and the other Financing Documents shall be and remain
unchanged and in full force and effect in accordance with their respective terms, are hereby ratified and confirmed in all respects.

 

	SECTION 9.	Governing
Law. This Amendment shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York,
without regard to conflicts of law principles that would require the application of laws of another jurisdiction.
	 	 
	SECTION 10.	Financing
Document. This Amendment shall be deemed to be a Financing Document for all purposes.
	 	 
	SECTION 11.	Severability.
Wherever possible, each provision of this Amendment shall be interpreted in such a manner as to be effective and valid under applicable
law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions
of this Amendment.
	 	 
	SECTION 12.	Counterparts.
This Amendment may be executed by one or more of the parties hereto on any number of separate counterparts, each of which shall
be deemed an original and all of which, taken together, shall be deemed to constitute one and the same instrument. Delivery of
an executed counterpart of this Amendment by facsimile or other electronic transmission shall be as effective as delivery of a
manually executed counterpart hereof.
	 	 
	SECTION 13.	Lender
Direction. Each of the undersigned Lenders hereby directs each of the Administrative Agent and the Collateral Agent to execute
and deliver this Amendment and to perform its respective obligations hereunder. The undersigned Lenders agree and direct that no
other document (including without limitation any opinion) is required in connection with this Amendment.
	 	 	 

 

[Signature Pages Follow]

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be executed by their respective officers as of the day and year first written
above.

 

 

PACIFIC ETHANOL HOLDING CO. LLC, as a Borrower
and as Borrowers’ Agent

 

 

By:/s/ BRYON T. MCGREGOR

Name: Bryon
T. McGregor

Title: Chief
Financial Officer

 

PACIFIC ETHANOL MADERA LLC, as a Borrower

 

 

By:/s/ BRYON T. MCGREGOR

Name: Bryon
T. McGregor

Title: Chief
Financial Officer

 

 

PACIFIC ETHANOL COLUMBIA, LLC, as a Borrower

 

 

By:/s/ BRYON T. MCGREGOR

Name: Bryon
T. McGregor

Title: Chief
Financial Officer

 

 

PACIFIC ETHANOL STOCKTON LLC, as a Borrower

 

 

By:/s/ BRYON T. MCGREGOR

Name: Bryon
T. McGregor

Title: Chief
Financial Officer

 

 

PACIFIC ETHANOL MAGIC VALLEY, LLC, as a Borrower

 

 

By:/s/ BRYON T. MCGREGOR

Name: Bryon
T. McGregor

Title: Chief
Financial Officer

 

 

PE OP CO., as Pledgor

 

 

By:/s/ BRYON T. MCGREGOR

Name: Bryon
T. McGregor

Title: Chief
Financial Officer

 

 

WELLS FARGO BANK, N.A.,
as Administrative Agent and Collateral Agent

 

 

By:/s/ MICHAEL ROTH

Name: Michael
Roth

Title: V.P.

 

Signature Page to Amendment to Second
Amended and Restated Credit Agreement

 

    	 	 	 

     

    

 

The undersigned Lender
acknowledges and agrees that this signature page shall be fully valid and binding upon such Lender upon its execution and delivery
by such Lender to the Administrative Agent and may not thereafter be revoked, terminated or cancelled by such Lender.

 

 

Credit Suisse Loan Funding LLC, as Lender

 

 

By:/s/ ROBERT HEALEY

Name: Robert
Healey

Title: Authorized Signatory

 

 

By:/s/ MICHAEL WOTANOWSKI

Name: Michael
Wotanowski

Title:Authorized Signatory

 

 

 

 

Signature Page to Amendment to Second
Amended and Restated Credit Agreement

    	 	 	 

     

    

 

The undersigned Lender
acknowledges and agrees that this signature page shall be fully valid and binding upon such Lender upon its execution and delivery
by such Lender to the Administrative Agent and may not thereafter be revoked, terminated or cancelled by such Lender.

 

 

Pacific Ethanol, Inc., as Lender

 

 

By:/s/ BRYON T. MCGREGOR

Name: Bryon
T. McGregor

Title: Chief
Financial Officer

 

 

 

 

 

Signature Page to Amendment to Second
Amended and Restated Credit AgreementExhibit 10.14

 

CONFIDENTIAL TREATMENT REQUESTED

 

THE
PORTIONS OF THIS AGREEMENT MARKED WITH ASTERISKS WITHIN BRACKETS (“[***]”) HAVE BEEN OMITTED PURSUANT TO A REQUEST
FOR CONFIDENTIAL TREATMENT UNDER 17 C.F.R. SECTIONS 200.80(B)(4), 200.83 AND 230.406.
A COMPLETE COPY OF THIS AGREEMENT HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.

 

EXECUTION COPY

 

exclusive
license Agreement

 

This Exclusive License
Agreement (this “Agreement”) is dated as of September 30, 2015 (the “Effective Date”), and
is by and between ELAN PHARMA INTERNATIONAL LIMITED, a company organized under the laws of the Republic of Ireland, with offices
located at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (“Elan”) and FLAMEL IRELAND LIMITED,
a company organized under the laws of the Republic of Ireland, with offices located at 2nd Floor, Block 10, Unit 1 Blanchardstown
Corporate Park, Ballycoolin, Dublin 15 Ireland (“Flamel”).

 

RECITALS

 

A.           Flamel has technology
called LiquiTime® that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension
formulation.

 

B.           Elan has substantial
experience in developing, selling and marketing pharmaceutical products in the over-the counter, non-prescription (“OTC”)
pharmaceutical markets.

 

C.           Flamel has begun
working on developing extended release versions utilizing LiquiTime® of Ibuprofen liquid suspension (the “Ibuprofen
Product”) and Guaifenesin liquid suspension (the “Guaifenesin Product” and collectively with the Ibuprofen
Product, the “Initial Products” and each an “Initial Product”).

 

D.           For the Initial
Products and certain additional extended release OTC products identified by the Parties in the future, each utilizing LiquiTime®
(each an “Additional Product” and collectively the “Additional Products” and collectively
with the Initial Products the “Products” and each a “Product”), Flamel will develop and obtain
marketing authorizations for the Products, transfer the marketing authorizations for these Products to Elan upon their approval
and be paid a royalty by Elan on its sales of the Products; all on the terms and conditions set forth in this Agreement.

 

    	 	 
[Confidential Treatment Requested]
	 

     

    

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

		1.	Definitions.

 

As used in this Agreement,
the following terms have the meanings indicated below:

 

“Additional
Product” or “Additional Products” has the meaning set forth in the Recitals hereof.

 

“Additional
Product Requirement” has the meaning set forth in Section 5.4 hereof.

 

“Act”
means the United States Federal Food, Drug and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder.

 

“Affiliate”
means, with respect to any Person, any other Person directly or indirectly controlled by, controlling, or under common control
with such Person. For such purposes, the term “control” means, whether used as a noun or a verb, the possession, directly
or indirectly, of the power to affirmatively direct, or affirmatively cause the direction of, the management and policies of an
entity, whether through the ownership of voting securities, by contract or otherwise (which would include the ownership, directly
or indirectly, of more than 50% of the voting stock or equity interest of the subject Person, or such other relations as, in fact,
result in the right to direct the management and policies of the subject Person).

 

“Agreement”
has the meaning set forth in the Preamble hereof.

 

“cGMP”
means those current Good Manufacturing Practices required by the FDA to be followed in connection with the manufacturing, handling,
storing and controlling of pharmaceutical products in the United States, as defined from time to time by the Act, as amended, or
any successor laws or any regulations related thereto.

 

“Clinical
and Regulatory Activities” has the meaning set forth in Section 4.2 hereof.

 

“Coated API”
has the meaning set forth in Section 5.5 hereof.

 

“Coated API
Agreement” has the meaning set forth in Section 5.5 hereof.

 

“Commercial
Manufacturing Scale-Up Activities” has the meaning set forth in Section 4.3 hereof.

 

“Commercial
Launch Date” means, with respect to each Product, the date of Elan’s first sale of such Product to Third Parties
on a commercial basis in the Territory, which date shall be no later than (i) sixty (60) days following delivery to Elan of the
commercial launch quantities of the Ibuprofen Product; and (ii) sixty (60) days after FDA approval of the Regulatory Filing for
the Guaifenesin Product and each Additional Product.

 

    	 	2	 
	 	[Confidential Treatment Requested]
	 

     

    

 

“Competing
Product” means, with respect to any Product, any extended release liquid product containing the same active pharmaceutical
ingredient, in the same strength as such Product in the case of monotherapy products or the same combination of active pharmaceutical
ingredients as such Product in the case of combination therapy products such that such product would reasonably be considered as
substitutable for such Product.

 

“Confidential
Information” means all proprietary materials, data or other information (whether or not patentable) regarding a Person’s
knowhow, products, business information or objectives, that are designated as confidential in writing by the disclosing party,
whether by letter or by the use of an appropriate stamp or legend, prior to or at the time any such material, data or other information
is disclosed by such Person to the recipient. Notwithstanding the foregoing, materials, data or other information that are disclosed
by a Person in writing without an appropriate letter, stamp or legend, or that are orally, electronically or visually disclosed
by a Person, also constitute Confidential Information of such Person if (i) within thirty (30) calendar days after such disclosure,
such Person delivers to the recipient a written document or documents describing the materials, data or other information indicating
that such materials, data or other information constitute Confidential Information, and referencing the place and date of such
oral, visual, electronic or written disclosure and the names of the persons to whom such disclosure was made, or (ii) such materials,
data or other information are of the type that are customarily considered to be confidential information by Persons engaged in
activities that are substantially similar to the activities being engaged in by the Persons exchanging such information. Confidential
Information does not include any information that is (i) already known to the recipient prior to the date of disclosure to the
recipient as evidenced by the recipient’s written records made prior to such date, (ii) publicly known prior to or after
disclosure other than through unauthorized acts or omissions of the recipient, (iii) disclosed in good faith to the recipient by
a Third Party lawfully and contractually entitled to make such disclosure or (iv) developed by or for the recipient without the
use of any Confidential Information of the disclosing party, as evidenced by the recipient’s written records.

 

“Contract
Year” means each one (1) year period during the Term with the first such one (1) year period commencing on the Effective
Date and ending on the day immediately preceding the one (1) year anniversary of the Effective Date, and each subsequent one (1)
year period commencing on the subsequent anniversary of the Effective Date.

 

“Damages”
has the meaning set forth in Section 7.1 hereof.

 

“Effective
Date” has the meaning set forth in the Preamble hereof.

 

“Elan”
has the meaning set forth in the Preamble hereof.

 

“Elan Fiscal
Quarter” means each of the four (4) fiscal quarters used by Elan for financial reporting purposes.

 

“Elan Indemnitees”
has the meaning set forth in Section 7.1 hereof.

 

    	 	3	 
	 	[Confidential Treatment Requested]
	 

     

    

 

“Elan
Net Sales” means, with respect to the aggregate amount of each Product sold by Elan or its Affiliates, the gross
sales (for purposes of determining whether a given sale occurs during a computation period, such Product will be considered sold
as of the date of shipment by Elan or its Affiliates to its customers), less the sum of the following (to the extent actually
incurred or accrued): (i) any and all credits for such Product returns during such period, including, but not limited to, credits
for returned, unsold, or short-dated Product, allowances granted or included in the invoice, reasonable cash discounts, customer
program accruals (overbills, administrative fees, third party rebates, sales brokerage, and volume rebates), other adjustments
and rebates, including but not limited to Medicaid and other state or governmental rebates, charge backs, floor stock adjustments,
and similar items that may be estimated in accordance with GAAP to the extent actually incurred or accrued; (ii) shipping costs,
sales and excise Taxes, other consumption Taxes, or other governmental charges to the extent actually included in gross sales;
and (iii) the amount of any receivables that have been included in gross sales and are deemed to be uncollectible according to
Elan’s or it Affiliates’ internal accounting principles and GAAP, with such bad debt deduction applied against gross
sales in the period in which such receivables are written off and shall be exclusive of any bad debt or uncollectible receivables
of Elan or its Affiliates unrelated to any such Product sold by Elan or its Affiliates.

 

“Elan Subcontractor”
has the meaning set forth in Section 4.2 hereof.

 

“FDA”
means the United States Food and Drug Administration.

 

“Field”
means the OTC pharmaceutical markets.

 

“Flamel”
has the meaning set forth in the Preamble hereof.

 

“Flamel Indemnitees”
has the meaning set forth in Section 7.2 hereof.

 

“Flamel Know-How”
means all trade secrets, knowledge, technology, specifications, inventions, assays, means, methods, processes, controls, practices,
formulas, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures,
computer programs, apparatuses, specifications, manufacturing procedures, test procedures and purification and isolation techniques,
quality controls, the identity and amounts of ingredients, (whether or not confidential, proprietary, patented or patentable) in
written, electronic or any other form, and all improvements, whether to the foregoing or otherwise, and other discoveries, developments
and inventions; in each case, applying or pertaining to (i) Flamel’s LiquiTime® technology for developing modified/controlled
release oral pharmaceutical products in a liquid suspension formulation; and (ii) the Laboratory Development Activities, the Clinical
and Regulatory Activities and the Commercial Manufacturing Scale-Up Activities of Flamel for each Product.

 

“Flamel Patents”
means (i) the issued patent identified as UD 7,906,145 and any extensions, reissues or reexaminations thereof; and (ii) any patent
applications throughout the world claiming priority of patent applications identified in US 7,906,145 and any patents that may
issue therefrom.

 

    	 	4	 
	 	[Confidential Treatment Requested]
	 

     

    

 

“Flamel Patents
Termination Date” means the earlier of (i) the date the Flamel Patents expire in the Territory; or (ii) the date the
Flamel Patents are revoked by the United States Patent and Trademark Office.

 

“Flamel Technology”
means, collectively, the Flamel Patents and the Flamel Know-How.

 

“Force Majeure
Event” has the meaning set forth in Section 11.7 hereof.

 

“GAAP”
means generally accepted accounting principles applied in a consistent manner in the United States of America.

 

“Governmental
Body” means any national, state, provincial, or other political subdivision thereof or any governmental or regulatory
entity or agency with legal authority to exercise executive, legislative, judicial, regulatory or administrative functions in the
Territory or the jurisdiction in which Product is manufactured.

 

“Guaifenesin
Product” has the meaning set forth in the Recitals hereof.

 

“Ibuprofen
Product” has the meaning set forth in the Recitals hereof.

 

“Indemnified
Party” has the meaning set forth in Section 7.3 hereof.

 

“Indemnifying
Party” has the meaning set forth in Section 7.3 hereof.

 

“Initial Product”
or “Initial Products” has the meaning set forth in the Recitals hereof.

 

“Insolvent”
means, with respect to any Person, such Person (i) making an assignment for the benefit of creditors; (ii) filing or having filed
against it a petition in bankruptcy; (iii) having a receiver appointed for its assets; or (iv) being dissolved or liquidated.

 

“Intellectual
Property Rights” means, collectively, all of the following intangible legal rights in the Territory, whether or not filed,
perfected, registered or recorded and whether now or hereafter existing, filed, issued or acquired: (i) patents, patent disclosures,
patent rights, including any and all continuations, continuations-in-part, divisionals, reissues, reexaminations, utility model,
industrial designs and design patents or any extensions thereof; (ii) rights associated with works of authorship, including without
limitation, copyrights, copyright applications and copyright registrations; (iii) rights in trademarks, trademark registrations
and applications therefor, trade names, service marks, service names, logos, or trade dress; (iv) rights relating to the protection
of formulae, trade secrets, know-how and Confidential Information; and (v) all other intellectual or proprietary rights in the
Territory.

 

“Laboratory
Development Activities” has the meaning set forth in Section 4.1 hereof.

 

“License Conversion
Event” means the earlier to occur of the following: (i) the Flamel Patents Termination Date; or (ii) the termination
of this Agreement by Elan pursuant to Section 10.2(a) hereof.

 

“OTC”
has the meaning set forth in the Recitals hereof.

 

    	 	5	 
	 	[Confidential Treatment Requested]
	 

     

    

 

“Party”
or “Parties” means, individually or collectively, as the case may be, Elan and Flamel.

 

“Person”
means any natural person, partnership, limited liability, company, trust, joint venture, joint stock company, association, unincorporated
organization, government or agency or political subdivision thereof, or other entity, whether acting in an individual, fiduciary
or other capacity.

 

“Product”
or “Products” has the meaning set forth in the Recitals hereof.

 

“Reasonable
Commercial Efforts” means, with respect to the subject Party, the level of efforts and resources equivalent to those
employed by the subject Party to market and distribute a product of similar market potential at a similar stage in its product
life to each Product, taking into account the establishment of such Product in the marketplace, the competitiveness of alternative
products in the marketplace, the conditions or prospects of regulatory approval, the profitability of such Product and other relevant
factors.

 

“Regulatory
Filing” means a New Drug Application filed pursuant to Section 505(b)(2) of the Act.

 

“Royalty”
means, with respect to each Product, the amount computed under the following royalty rates for that Product:

 

	Time Period	 	Marginal Royalty Rate
	 	 	 
	First five (5) years after Commercial Launch Date of Product	 	[***]% of Elan Net Sales
	Thereafter, until the expiration of the Term	 	[***]% of Elan Net Sales

 

“Special Damages”
has the meaning set forth in Section 7.4 hereof.

 

“Tax”
means any tax, levy, impost, duty or other charge or withholding of a similar nature (including any penalty or interest payable
in connection with any failure to pay or any delay in paying any of the same).

 

“Tax Deduction”
means any deduction or withholding for or on account of a Tax from any payment under this Agreement.

 

“Technology
Transfer” has the meaning set forth in Section 4.4 hereof.

 

“Term”
has the meaning set forth in Section 10.1 hereof.

 

“Territory”
means the United States, including its territories and possessions.

 

[***] Confidential treatment requested for deleted portion.

 

    	 	6	 
	 	[Confidential Treatment Requested]
	 

     

    

 

“Third Party”
means any Person other than the Parties and their Affiliates.

 

“UK Rx Markets”
has the meaning set forth in Section 2.2 hereof.

 

“VAT”
means (i) the value added Tax as provided for in the Value-Added Tax Consolidation Act 2010 (as amended) of Ireland; (ii) any Tax
imposed in compliance with the Council Directive of 28 November 2006 on the common system of value added Tax (EC Directive 2006/112);
and (iii) any other Tax of a similar nature, whether imposed in a member state of the European Union in substitution for, or levied
in addition to, such Tax referred to in clause (i) and (ii) above, or imposed elsewhere.

 

		2.	Terms of License.

 

2.1     Grant of License.
During the Term, Flamel hereby grants to Elan, and Elan hereby accepts from Flamel, an exclusive (even as to Flamel except for
Flamel, its Affiliates or its subcontractors solely to perform their obligations and duties hereunder or in connection therewith),
sublicensable, license solely in the Field in the Territory to use the Flamel Technology, including all Intellectual Property
Rights pertaining thereto, to sell and market the Products and otherwise exploit the Regulatory Filings for the Products in the
Field in the Territory and after the Flamel Patents Termination Date to also develop and register additional pharmaceutical products
in the Field in the Territory. Elan acknowledges and agrees that the exclusivity granted to Elan in this license will, prior to
any License Conversion Event, be contingent on Elan continuing to satisfy the Additional Product Requirement and the Competing
Product Requirement.

 

2.2      Expansion
of Field and Territory. Flamel hereby acknowledges Elan’s interest in commercializing the Flamel Technology in the Rx
markets in the United Kingdom, which markets are outside of the Field and the Territory (the “UK Rx Markets”).
Flamel agrees to discuss the UK Rx Markets in good faith with Elan prior to offering this business to any Third Party.

 

2.3      License Conversion
Event. Upon the occurrence of any License Conversion Event, (i) the license to the Flamel Technology will become perpetual,
fully-paid and irrevocable in the Field and in the Territory, and (ii) Elan’s obligation to pay Royalties will cease; in
each case, with respect to each Product impacted by the circumstances giving rise to such License Conversion Event (but not for
any Products not so impacted).

 

		3.	Financial Provisions

 

The sole and exclusive consideration payable
to Flamel by Elan for the license granted above, Flamel’s development work described below and all other obligations of Flamel
under this Agreement or services performed by Flamel, its Affiliates or subcontractors in connection with the Initial Products
is as follows:

 

3.1      License Fee.
Elan shall pay to Flamel a one-time, license fee of Six Million Dollars ($6,000,000) within thirty (30) days after the Effective
Date.

 

    	 	7	 
	 	[Confidential Treatment Requested]
	 

     

    

 

3.2      Milestone
Payments. With respect to each Initial Product Elan shall pay to Flamel the following milestone Payments within thirty (30)
days after the occurrence of each event described below with respect to such Initial Product:

 

		·	[***] Dollars ($[***])– upon submission of the NDA transfer letter by Flamel to the FDA notifying the FDA of the transfer
of the Regulatory Filing to Elan after FDA approval of such Initial Product.

 

		·	[***] Dollars ($[***]) – upon Commercial Launch Date of such Initial Product.

 

3.3      Royalty.
Within ten (10) days after the end of each Elan Fiscal Quarter, Elan shall provide Flamel with an initial estimate of the Royalties
due to Flamel for such Elan Fiscal Quarter. Elan shall pay the Royalty to Flamel in respect of Product sales taking place during
that Elan Fiscal Quarter within sixty (60) days after the end of that Elan Fiscal Quarter.

 

3.4      Recordkeeping
and Audit Right. Elan shall maintain complete and accurate records pertaining to its computation of the Royalty payable under
this Agreement during Term and for a period of two (2) years after the termination or expiration of this Agreement. On an annual
basis or more frequently for good cause shown, during the Term and the retention period noted above, upon reasonable advance notice
Flamel may appoint at its own expense an independent public accounting firm to audit the relevant records of Elan supporting its
computation of the Royalty. Flamel shall be entitled to any amounts determined by the independent public accounting firm to have
been underpaid by Elan, within forty-five (45) calendar days after demand therefor has been received by Elan, which demand shall
include the complete audit report prepared by the independent public accounting firm. The determination by the independent public
accounting firm will be binding on the Parties absent manifest error. The fees of the independent public accounting firm shall
be borne by Flamel unless the report of the independent public accounting firm shows an underpayment by Elan of more than 10% in
which case Elan shall be responsible for payment of the independent public accounting firm’s fees.

 

		4.	Product Development and Technology Transfer.

 

4.1      Laboratory
Development Activities. With respect to each Initial Product and upon mutual agreement of the Parties with respect to the Additional
Products, Flamel, or one of its Affiliates or subcontractors, will be responsible for Product formulation, method validation, pilot
studies and all other activities necessary to create a lab-scale version of such Product (the “Laboratory Development
Activities”).

 

4.2      Clinical
and Regulatory Activities. With respect to each Initial Product and upon mutual agreement of the Parties with respect to the
Additional Products, Flamel, or one of its Affiliates or subcontractors, will be responsible for performing all clinical studies,
including any bio-equivalence studies, and for making the Regulatory Filing and obtaining approval of the Regulatory Filing (collectively,
the “Clinical and Regulatory Activities”).

 

[***] Confidential treatment requested for deleted portion.

 

    	 	8	 
	 	[Confidential Treatment Requested]
	 

     

    

 

4.3      Commercial
Manufacturing Scale-Up Activities. With respect to the Initial Products and upon mutual agreement of the Parties with respect
to each Additional Product, Flamel, or one of its Affiliates or subcontractors, will also be responsible for scaling up such Product
for commercial production, manufacturing exhibit batches for pivotal studies (conducted by Flamel as part of the Clinical and Regulatory
Activities) and producing exhibit batches for stability testing (the “Commercial Manufacturing Scale-Up Activities”).
Although Flamel will be responsible for all Commercial Manufacturing Scale-Up Activities, it will engage Elan or one of its Affiliates
as a subcontractor (the “Elan Subcontractor”) to perform the Commercial Manufacturing Scale-Up Activities for
each Product (except for the Ibuprofen Product for which Flamel has engaged another subcontractor to perform the Commercial Manufacturing
Scale-Up Activities as of the Effective Date). Flamel and the Elan Subcontractor will enter into a separate agreement covering
the legal and commercial terms governing the Commercial Manufacturing Scale-Up Activities for each Product; provided that
such agreement will provide that Elan’s fees for the Commercial Manufacturing Scale-Up Activities for each Product shall
be charged to Flamel at Elan’s fully-allocated cost and when added together with the cost of the Technology Transfer as described
in Section 4.4 below may not exceed [***] Dollars ($[***]) per Product, provided further, that such agreement will
also provide that such limitation to will not apply to any work required due to Product reformulation, test failures, specification
changes or any other factor that is not under Elan’s reasonable control. Notwithstanding the foregoing, in the event that
Elan or the Elan Subcontractor cannot successfully perform the Commercial Manufacturing Scale-Up Activities for a Product within
a reasonable period of time, Flamel shall have the right to engage a Third Party to perform such Commercial Manufacturing Scale-Up
Activities and to manufacture and supply such Product to Elan on a commercial basis until such time as Elan or the Elan Subcontractor
can successfully perform such activities at a price to Elan of no more than cost plus [***] percent ([***]%).

 

4.4      Technology
Transfer; Commercial Manufacturing - Ibuprofen Product. To effect the transition of the Commercial Manufacturing Scale-Up Activities
to Elan, Flamel, or one of its Affiliates or subcontractors, will transfer to Elan all Flamel Know How for that Product obtained
in performing the Laboratory Development Activities and the Clinical and Regulatory Activities (the “Technology Transfer”).
In the case of the Ibuprofen Product, the Technology Transfer will occur upon FDA approval of the Regulatory Filing for that Product.
Furthermore, the Parties acknowledge and agree that in the case of the Ibuprofen Product, Flamel, its Affiliates or its subcontractor
will be responsible for the commercial supply of the Ibuprofen Product to Elan at Flamel’s cost or Flamel’s acquisition
cost of the Ibuprofen Product until the completion of the Technology Transfer and Elan or the Elan Subcontractor has received FDA
approval to manufacture commercial supplies of the Ibuprofen Product. In the event that Flamel terminates this Agreement pursuant
to Section 10.2, Elan shall immediately transfer back to Flamel all of the Flamel Know-How referenced above in this Section
4.4.

 

4.5      Regulatory
Process and Transfer of Regulatory Filing. For each Product, Flamel, or one of its Affiliates or subcontractors, will submit
the Regulatory Filing in Flamel’s or its Affiliate’s name and conduct all communications with the FDA. Elan will provide
assistance to Flamel in connection with preparing, and obtaining approval of, the Regulatory Filing, provided that any such assistance
will be performed on a time and materials basis unless within the scope of the Commercial Manufacturing Scale-Up Activities. Flamel,
or one its Affiliates or subcontractors, will transfer the Regulatory Filing to Elan upon the earlier of the approval of the applicable
Regulatory Filing or the termination of this Agreement; provided that Flamel shall have a right to reference and use any data (clinical
or otherwise) with respect to the Products; and provided further that in the event of a termination of the Agreement by Flamel
pursuant to Section 10.2, Elan shall immediately transfer the Regulatory Filing and any related data, back to Flamel.

 

[***] Confidential treatment requested for deleted portion.

 

    	 	9	 
	 	[Confidential Treatment Requested]
	 

     

    

 

4.6      Intellectual
Property Rights. Subject to the license granted by Flamel to Elan under Section 2.1, all Intellectual Property Rights
and intellectual property, arising as a result of the activities and services performed by Flamel under this Agreement shall be
the sole and exclusive property of Flamel. Additionally, Elan agrees that Flamel shall have a royalty free, fully paid up, sublicensable
license to any intellectual property and Intellectual Property Rights developed by Elan, the Elan Subcontractor or its Affiliates
derived from the Flamel Technology.

 

		5.	Elan’s Marketing, Sale and Distribution of Product.

 

5.1      Elan’s
Responsibilities. Elan shall use Reasonable Commercial Efforts to market and sell Product to customers that are located in
the Field in the Territory. Under this Agreement, Elan shall not be permitted to (i) sell Product to, or solicit orders for sale
of Product from, any existing or prospective customer located outside the Territory, (ii) deliver or tender (or cause to be delivered
or tendered) Product outside the Territory, (iii) sell Product to, or solicit any sale of Product from, a customer in the Territory
for which Elan knows or has reason to know intends to resell Product outside the Territory; or (iv) prior to any License Conversion
Event, bundle any Product with another product of Elan or one of its Affiliates where such bundling results in any discount applied
to such Product being proportionally greater than the discount applied to any other products.

 

5.2      Expenses.
Elan is responsible for paying all its expenses in performing its sales and marketing obligations set forth in this Article
5.

 

5.3      Elan’s
Selling Price of Product. Subject to Section 5.1(iv) above, Elan has sole discretion over establishing the price at
which it sells Product and is responsible for invoicing customers.

 

    	 	10	 
	 	[Confidential Treatment Requested]
	 

     

    

 

5.4      Exclusivity;
Additional Product Requirement; Competing Product Requirement. Elan will be the exclusive licensee for the Flamel Technology
in the Field in the Territory. Further, Flamel agrees that it will not, on its own or through an Affiliate, use the Flamel Technology
in the Field in the Territory for any commercial purpose other than to perform its obligations and duties under this Agreement.
The exclusivity granted by Flamel to Elan in this Section 5.4 will terminate in the event that Elan fails to satisfy the
Additional Product Requirement or the Competing Product Requirement (as each is defined below). Elan will designate an Additional
Product to be developed by Flamel during each of the first five (5) Contract Years on terms and conditions reasonably acceptable
to the Parties (the “Additional Product Requirement”). In the event that the Parties cannot agree on the terms
and conditions to satisfy the Additional Product Requirement, then, at Elan’s option and decision, Flamel or its Affiliates
or subcontractors shall either (A) develop the Additional Product for Elan and Elan shall pay Flamel, when due and payable, Flamel’s
or its Affiliates’ fully-allocated cost (including the costs associated with any activities performed by any subcontractor)
associated with performing the services) plus [***] percent ([***]%) and Elan shall pay Flamel (i) milestone payments of: (x) $[***]
upon submission of the Regulatory Filing transfer letter to FDA notifying the FDA of the transfer of the of the Regulatory Filing
to Elan after FDA approval of such Additional Product and (y) $[***] upon commercial launch of such Additional Product and (ii)
the same Royalty as the Royalty paid for the Initial Products; or (B) develop and commercialize such Additional Product with a
Third Party on commercial terms no less favorable to Flamel than the commercial terms set forth in clause (A) above. Elan
acknowledges and agrees that in the case of clause (B) in the preceding sentence where such Additional Product is developed
by a Third Party, Elan shall still have the obligation to designate a replacement Product for such Contract Year. Furthermore,
as an additional condition to retaining the exclusivity set forth in this Section 5.4, during the Term, Elan agrees that
it shall not directly or through an Affiliate or with a Third Party, manufacture, sale, market or distribute a Competing Product.
Elan further agrees and acknowledges that Elan in addition to forgoing the exclusivity by selling a Competing Product, Elan shall
pay Flamel, a royalty (in the same percentage and for the same time period) that is equal to the Royalty on the Products as set
forth herein for any Competing Product sold.

 

5.5      Key Commercial
Terms. Not later than six (6) months prior to the expected date of approval of the Regulatory Filing for each Product, the
Parties will enter a commercial agreement for the supply by Flamel or one of its Affiliates or subcontractors to Elan of the extended
release active pharmaceutical ingredient for such Product, coated by Flamel or one of its Affiliates or subcontractors with extended-release
beads using the Technology (“Coated API”). The commercial agreement for Flamel’s or one of its Affiliates’
or subcontractors’ supply of Coated API to Elan (the “Coated API Agreement”) will include the terms set
forth in Schedule 5.5 attached hereto and other terms agreed upon by the Parties.

 

		6.	Representations and Warranties.

 

Each Party represents
and warrants to the other Party that (i) it is duly organized, validly existing and in good standing under the laws of its jurisdiction
of organization, (ii) the execution, delivery and performance of this Agreement by such Party has been duly authorized, and this
Agreement is a valid and binding obligation of such Party enforceable against such Party in accordance with its terms, (iii) the
execution, delivery and performance of this Agreement by such Party will not result in any breach of its organizational documents
or any breach or violation of any agreement or instrument to which it is a party or bound or of any law, regulation, order or decree
to which it is subject or by which its assets are bound, (iv) such Party has full power and authority to perform its obligations
and grant the rights it has granted to the other Party as provided in this Agreement, (iv) none of its employees, officers, directors,
or agents has been: (a) debarred, or convicted of a crime for which a Person can be debarred, under Section 306(a) of the United
States Federal Generic Drug Enforcement Act of 1992, as amended, or (b) to the best of its knowledge, have been threatened with
debarment or indictment for such a crime by a Governmental Body.

 

[***] Confidential treatment requested for deleted portion.

 

    	 	11	 
	 	[Confidential Treatment Requested]
	 

     

    

 

If any debarment or conviction
occurs while this Agreement is in force and effect, the Party involved with such debarment or conviction shall promptly provide
notification to the other Party.

 

EXCEPT AS PROVIDED
IN THIS ARTICLE 6, NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED
WARRANTY AS TO MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

 

		7.	Patent Indemnification and Excluded Damages.

 

7.1      Patent Indemnification.
Except in the case of Elan’s gross negligence or willful misconduct, Flamel shall defend, indemnify and hold Elan, including
its Affiliates and their respective directors, officers, shareholders, employees, servants and agents harmless (the “Elan
Indemnitees”) from and against any and all losses, liabilities, damages, costs and expenses, including reasonable attorneys’
fees and disbursements in connection with any and all Third-Party suits, investigations, claims or demands (collectively, “Damages”);
in each case, resulting from or in connection with the Flamel Patents, except, in each case, for those Damages for which Elan has
an obligation to indemnify the Flamel Indemnitees pursuant to Section 7.2, as to which Damages each Party shall indemnify
the other Party to the extent of its respective liability for such Liabilities.

 

7.2      Commercialization
Indemnification. Except in the case of Flamel’s gross negligence or willful misconduct, Elan shall defend, indemnify
and hold Flamel, including its Affiliates and their respective directors, officers, shareholders, employees, servants and agents
harmless (the “Flamel Indemnitees”) from and against any Damages from or in connection with Elan’s manufacturing,
sale, marketing and distribution of the Products; except, in each case, for those Damages for which Flamel has an obligation to
indemnify the Elan Indemnitees pursuant to Section 7.1, as to which Damages each Party shall indemnify the other Party to
the extent of its respective liability for such Damages.

 

7.3      Indemnification
Procedures. Upon the occurrence of any event giving rise to a right to seek indemnification hereunder, Elan or Flamel, as the
case may be (the “Indemnified Party”) shall give notice of such claim, action or proceeding to the other Party
(the “Indemnifying Party”) within ten (10) calendar days after it becomes known to Elan, except that the failure
to give such notice shall not relieve the Indemnifying Party of its obligations to indemnify unless such failure materially and
adversely affects the defense of such action or increases the liability of the Indemnifying Party. Within ten (10) calendar days
after receipt of such notice, the Indemnifying Party shall notify the Indemnified Party as to whether or not the Indemnifying Party
wishes to take over the defense of such action, and if the Indemnifying Party fails to provide such notice, the Indemnified Party
shall be entitled to take over the defense of the action. Upon proper notification by the Indemnifying Party of its intention to
defend the claim, the Indemnifying Party shall engage counsel reasonably satisfactory to the Indemnified Party to assume the investigation
and defense of the claim and shall keep the Indemnified Party and its counsel currently informed as to all material aspects of
the claim and its investigation and defense. The Indemnified Party may, in such case, engage counsel to assist in the investigation
and defense of the claim but shall not be entitled to reimbursement for any expenses related to the engagement of such counsel.
If the Indemnifying Party elects not to assume the investigation and defense of the claim, or fails to make any election within
the time period herein provided, or if in the reasonable opinion of counsel to the Indemnified Party, the Indemnified Party has
available to it defenses that are contrary to the interests of the Indemnifying Party in any such action, then the Indemnified
Party may engage its own counsel for such investigation and defense and shall be entitled to full indemnification for the costs
thereof.

 

    	 	12	 
	 	[Confidential Treatment Requested]
	 

     

    

 

7.4      Excluded
Damages. EXCEPT IN THE CASE OF A PARTY’S GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR A BREACH OF SECTION 9.1,
IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER
SIMILAR DAMAGES, INCLUDING WITHOUT LIMITATION LOSS OF REVENUE OR LOSS OF PROFITS (“COLLECTIVELY, “SPECIAL DAMAGES”),
EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH SPECIAL DAMAGES, PROVIDED THAT EITHER PARTY WILL BE LIABLE FOR SUCH
SPECIAL DAMAGES TO THE EXTENT IT IS OBLIGATED TO INDEMNIFY THE OTHER PARTY UNDER THIS AGREEMENT IN RESPECT OF A THIRD-PARTY CLAIM
AGAINST THE OTHER PARTY THAT INCLUDES SUCH SPECIAL DAMAGES.

 

		8.	Insurance.

 

8.1      General
Requirements. Each of Flamel and Elan shall obtain and maintain at its expense during the Term and for a period of at least
five (5) years after the termination or expiration of this Agreement, all insurance coverage required by law as well as appropriate
insurance coverage to protect against any and all claims or liabilities that may arise directly or indirectly as a result of its
performance of its obligations under this Agreement. Insurance shall be placed with a carrier with an A.M. Best rating of at least
A- for financial strength and a size rating of at least VIII. Coverage shall be occurrence based, unless occurrence coverage is
unavailable, in which case “claims made” coverage is acceptable, provided retroactive coverage is provided prior to
the inception of the business relationship between Elan and Flamel. None of the requirements contained herein as to coverage types
or limits of insurance required to be maintained by the Parties shall be construed to limit in any manner the liability of either
Party to the other Party hereunder.

 

8.2      Proof
of Insurance. Each Party shall deliver to the other Party, within thirty (30) calendar days after the execution of this Agreement,
Certificates of Insurance evidencing the following: (i) the effective and expiration dates of the policies; (ii) for each of the
policies, the limits of liability per occurrence and in the aggregate; (iii) that the other Party has been named as an additional
insured under products liability and excess liability policies; and (iv) that the other Party shall be given thirty (30) calendar
days advance notice prior to any cancellation, non-renewal or material change of any of the policies. Each Party shall provide
to the other Party current Certificates of Insurance evidencing renewal of insurance throughout the Term promptly after any change
or renewal of the policies.

 

8.3      Specific
Minimum Coverages. At a minimum, each Party shall keep the following policies in place during the term of this Agreement:

 

    	 	13	 
	 	[Confidential Treatment Requested]
	 

     

    

 

	Required Coverages and Minimum Policy Limit
	 
	Required Coverage	 	Policy Limit	 
	 	 	 	 	 
	Worker’s Compensation	 	 	Statutory	 
	 	 	 	 	 
	General Liability: Bodily Injury & Property Damage	 	$	5,000,000	 
	 	 	 	(U.S. Combined Single Limit, per occurrence)	 
	 	 	 	 	 
	Product Liability	 	$	10,000,000	 
	 	 	 	 	 
	Excess Liability	 	$	5,000,000	 

 

		9.	Confidentiality.

 

9.1      Obligations
of Confidentiality. Neither Party will use or disclose to Third Parties any Confidential Information of the other Party (except
to comply with its obligations under this Agreement), except that each Party may disclose such Confidential Information to such
of its managers, officers, directors, employees and agents (and to such of the managers, officers, directors, employees and agents
of its Affiliates) as reasonably required it in connection with this Agreement and who agree in writing to be bound by confidentiality
obligations not less restrictive than those contained in this Agreement, and each Party shall ensure that such managers, officers,
directors, employees and agents comply with such obligations and shall be responsible for their failure to do so. Notwithstanding
the foregoing, such information may be (i) disclosed to any Governmental Body where such Confidential Information may be required
to be included in regulatory filings permitted under the terms of this Agreement or in patent applications filed within the United
States Patent and Trademark Office or corresponding international patent offices, (ii) provided to a Party’s employees, advisors
and consultants under appropriate terms and conditions including confidentiality provisions substantially equivalent to those in
this Agreement, for the purpose of such Party performing its obligations under this Agreement, (iii) published, if and to the extent
such publication has been approved by disclosing Party, or (iv) disclosed to the extent required by applicable laws or regulations
or as ordered by a court or other Governmental Body having competent jurisdiction. In each of the foregoing cases, the recipient
shall use its reasonable commercial efforts to limit the disclosure and maintain confidentiality to the extent possible. In the
case of a required disclosure under clause (iv) above, the Party required to make the disclosure shall promptly notify the original
disclosing Party and shall provide reasonable assistance, if requested by the original disclosing party, to assist the original
disclosing Party in its attempts to prevent or limit the disclosure at the original disclosing Party’s cost and expense.
If a Party is required by law or court order to provide a copy of this Agreement or any related document to any Third Party (except
in confidence as permitted by this Agreement), such Party shall redact Confidential Information from such document, except as otherwise
required by law. Each Party shall have the right to review and approve each redacted document prior to its submission to a Third
Party. The reviewing Party shall have a period of ten (10) calendar days to review the redacted document, except that in the case
of the order of a court or regulatory agency, the reviewing Party shall have the maximum reasonable amount of time.

 

    	 	14	 
	 	[Confidential Treatment Requested]
	 

     

    

 

9.2      Termination
of Agreement. Upon the expiration or termination of this Agreement, each Party shall return to the disclosing Party or destroy
all Confidential Information of the disclosing Party in tangible form in its possession; provided, that (i) the receiving Party
may retain one (1) copy of Confidential Information of the disclosing Party in its legal files solely for the purpose of demonstrating
the satisfaction of its continuing obligations of confidentiality under this Agreement, and (ii) if a License Conversion Event
has occurred, Elan may retain any documents needed to continue to exercise its rights under its license.

 

9.3      Injunctive
Relief. Each Party acknowledges that if it breaches any of the provisions of this Article 9, the other Party may not
have an adequate remedy at law and may suffer irreparable damage and injury and that, in addition to any other available rights
and remedies, the other Party shall be entitled to seek an injunction restricting the breaching Party from committing or continuing
any violation of such provisions.

 

		10.	Term and Termination.

 

10.1    Term.
This Agreement commences of on the Effective Date and will remain in effect, unless earlier terminated as set forth herein, with
respect to each Product, until the Flamel Patents Termination Date (the “Term”).

 

10.2    Termination.

 

(a)         Either Party
may terminate this Agreement or a particular Product from this Agreement by written notice to the other Party if the other Party
materially breaches this Agreement and fails to cure the material breach within forty-five (45) calendar days after written notice
of the material breach has been given to the breaching Party.

 

(b)         Either Party
may terminate this Agreement upon written notice to the other Party if the other Party becomes Insolvent.

 

(c)         Either Party
may terminate this Agreement upon thirty (30) days written notice in connection with a Force Majeure Event pursuant to Section
11.7 hereof.

 

10.3    Actions
Upon Termination. Upon termination or expiration of this Agreement for any reason, Elan may sell Product in its inventory as
of the date of termination, and, prior to any License Conversion Event, Elan shall pay to Flamel the Royalty for such sales in
accordance with Section 3.3 hereof.

 

		11.	Miscellaneous.

 

11.1    Each Party
Pays Own Costs. Except as expressly stated otherwise herein, each Party shall be responsible for the costs it incurs in performing
its obligations under this Agreement.

 

    	 	15	 
	 	[Confidential Treatment Requested]
	 

     

    

 

11.2  Currency.
All financial calculations and payments made by Elan to Flamel under this Agreement shall be made in U.S. Dollars. All other references
to “dollars” or “$” shall indicate U.S. Dollars.

 

11.3  Taxes.
All sums required to be paid under or in connection with this Agreement for Flamel Technology are to be treated as exclusive of
VAT, and Elan shall pay to Flamel an amount in respect of VAT properly chargeable on any amounts due under this Agreement in addition
to the sums otherwise payable. Flamel shall issue a valid VAT invoice in accordance with law. Elan shall make all payments to be
made by it without any Tax Deduction, unless a Tax Deduction is required by law.

 

11.4  Independent
Contractor. The relationship between Elan and Flamel is that of independent contractors, and nothing contained in this Agreement
or otherwise shall be deemed to create any other relationship, including employment, partnership, agency or joint venture, between
them. Neither Party shall have any authority to employ any Person as agent or employee for or on behalf of the other Party, or
to bind, or attempt to bind, the other Party to any obligation with any Third Party. Each Party has and retains full control and
supervision over the performance of its obligations hereunder and over the employment, direction, compensation and discharge of
all employees, agents and subcontractors it utilizes in the performance of such obligations. Each Party is responsible for its
acts and omissions and those of its employees, agents and subcontractors.

 

11.5  Advertising
and Publicity. Neither Party shall use the name or any trademark, trade name, logo or symbol of the other Party or the other
Party’s Affiliates, or disclose any matters relating to this Agreement, in any advertising, promotion, press/publicity releases,
written articles or communications without the prior consent of the other Party.

 

11.6  Cooperation.
The Parties agree to meet regularly and keep one another updated with respect to the activities set forth in Article 4 and Article
5 and the development, manufacturing, marketing and sale of the Products.

 

11.7  Force Majeure.
Neither Party shall be liable for delays in performance or nonperformance in whole or in part due to any causes that are beyond
its reasonable control and not due to its acts or omissions, such as acts of God, fire, strikes, embargo, acts of the government,
or other similar causes, but not acts that could be anticipated, such as raw material price increases, shortages of raw material
or an increase in demand for Product (each a “Force Majeure Event”), provided that if any Force Majeure Event
shall continue for a period of six (6) months or longer, then the Party whose performance has not been impacted by such Force Majeure
Event shall have the right to terminate this Agreement without liability upon notice to the Party whose performance has been so
impacted. Upon the occurrence of a Force Majeure Event, the Party delayed shall promptly give notice to the other Party.

 

11.8  Assignment
and Subcontracting. Other than to one of its Affiliates and to subcontractors with respect to Article 4 and Section
5.4 hereof, neither Party may assign this Agreement or subcontract any of its obligations under this Agreement, in whole or
in part, to any other Person without the prior consent of the other Party, which consent shall not be unreasonably withheld, delayed
or conditioned. Notwithstanding any permitted assignment under this Section 11.8, the assigning party will remain jointly
and severally liable for the obligations assigned.

 

    	 	16	 
	 	[Confidential Treatment Requested]
	 

     

    

 

11.9  Notices.
Any notice, communication, consent, approval, request, demand or statement required or permitted to be given hereunder shall be
in writing and deemed to have been sufficiently given when delivered in person or by registered or certified mail, postage prepaid,
return receipt requested or by overnight courier service, addressed as follows:

 

To Flamel:

 

Flamel Ireland Limited

c/o Flamel Technologies, SA

702 Spirit 40 Park Drive, Suite
108

Chesterfield, Missouri 63005

Attention: Legal Department

Facsimile: +16364991850

 

To Elan:

 

Elan Pharma International Limited

c/o L. Perrigo Company

515 Eastern Avenue

Allegan, Michigan 49010

Attn:   General Counsel

Facsimile: +12696731386

 

Any Party may, by notice
to the other, change the addresses and names given above.

 

11.10  Non-Waiver.
The failure of a Party to strictly enforce any of the terms or conditions of this Agreement shall not be considered as a waiver
of any right hereunder nor shall it deprive that Party of the right at some other time to insist upon strict adherence to that
term or condition or to any other terms or conditions.

 

11.11  Severability.
If any article, section, subsection, sentence or clause of this Agreement shall be adjudged illegal, invalid or unenforceable,
such illegality, invalidity or unenforceability shall not affect the legality, validity or enforceability of this Agreement as
a whole or of any article, subsection, sentence or clause hereof not so adjudged, and the remaining terms and provisions of this
Agreement will remain unimpaired and in full force and effect.

 

11.12  Section
Headings. All section headings herein are for convenience only and are not to be construed as a limitation of the scope of
the particular sections to which they refer.

 

11.13  Governing
Law and Jurisdiction. The validity, interpretation and performance of this Agreement shall be governed by and construed in
accordance with the laws of the State of New York without regard to its principles of conflicts of law.

 

    	 	17	 
	 	[Confidential Treatment Requested]
	 

     

    

 

11.14  Successors
and Assigns. This Agreement will apply to, inure to the benefit of and be binding upon the Parties hereto and upon their respective
successors and permitted assigns.

 

11.15  Survival
of Obligations. The termination or expiration of this Agreement shall not affect the survival and continuing validity of Section
2.3 (License Conversion Event); Article 3 (Financial Provisions); Article 7 (Indemnification and Excluded Damages);
Article 8 (Insurance); Article 9 (Confidentiality); Section 10.3 (Actions Upon Termination); and Article
11 (Miscellaneous) or of any other provision that is expressly or by implication intended to continue in force after such termination
or expiration.

 

11.16  Amendments.
No modification, alteration or amendment of this Agreement shall be binding upon the Parties unless contained in a writing signed
by a duly authorized agent for each respective Party and specifically referring hereto or thereto, as the case may be.

 

11.17  Entire
Agreement. This Agreement, together with any documents attached hereto, constitutes the entire agreement of the Parties with
respect to its subject matter and merges and supersedes all prior discussions and writings with respect thereto, including but
not limited to the Mutual Confidential Disclosure Agreement between Flamel and Perrigo Company plc dated as of December 3, 2014.

 

    	 	18	 
	 	[Confidential Treatment Requested]
	 

     

    

 

 

	 	ELAN PHARMA INTERNATIONAL LIMITED
	 	 	 
	 	By:	
	 	Name:	 
	 	Title:	Authorized Signatory
	 	 	 
	 	FLAMEL IRELAND LIMITED
	 	 	 
	 	By:	/s/ Phillandas T. Thompson
	 	Name:	Phillandas T. Thompson
	 	Title:	Authorized Signatory

 

    	 	19	 
	 	[Confidential Treatment Requested]
	 

     

    

 

Schedule
5.5

 

key commercial
terms for coated api agreement

 

	Subject Matter	 	Term
	 	 	 
	Price for Coated API	 	Fully-allocated cost of Flamel to supply Coated API until the termination of Royalty payments under Agreement; thereafter, plus an agreed-upon percentage mark-up.
	 	 	 
	Indemnification	 	Elan would defend, indemnify and hold Flamel harmless for any Product defects not caused by defects with Coated API, Flamel Technology or Flamel’s breach of its obligations under Coated API Agreement.
	 	 	 
	Term and Termination	 	May be terminated only upon termination of License and Development Agreement or due to either Party’s material breach (which in the case of Elan would be limited to non-payment).
	 	 	 
	Exclusions on Damages	 	Except in the case of a Party’s gross negligence or willful misconduct, in no event will either Party be liable to the other party for any special, indirect, incidental, consequential, punitive or other similar damages, including without limitation loss of revenue or loss of profits.
	 	 	 
	Responsibility For API Defects	 	Elan will source and be responsible for any defects with immediate release API; Flamel will source and be responsible for any defects with extended release API.
	 	 	 
	Warranties	 	Flamel will perform the API coating in accordance with cGMP and in a professional and workmanlike manner.
	 	 	 
	Governing Law	 	New York
	 	 	 
	Shipping Terms	 	FCA (Incoterms 2010) Allegan, Michigan.
	 	 	 
	Payment Terms	 	MSN 3
	 	 	 
	Recall Expenses	 	Each Party will be responsible for recalls to the extent of its fault.

 

    	 	20	 
	 	[Confidential Treatment Requested]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]